A Phase 3 Study of Bardoxolone Methyl in Patients With Diabetic Kidney Disease; AYAME Study
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1323 participants.
Also called NCT03550443
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,323 participants
- Sponsor
- Registry
-
NCT03550443
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Terminated
Technical summary
Registry record NCT03550443. Randomized; double masking; primary purpose treatment. Start 2018-05-30 (actual); primary completion 2022-11-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3 Study of Bardoxolone Methyl in Patients With Diabetic Kidney Disease; AYAME Study
- Condition
- Diabetic Kidney Disease
- Intervention (Drug)
- Bardoxolone methyl
- Intervention (Drug)
- Placebo
- Lead sponsor
- Kyowa Kirin Co., Ltd.
Record details
- Record id
cardio:ct-nct03550443- Content hash
a5de94799edfcf13d9351501a5d22cff07c2901676ff5520dfff49daf7703858